Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > What are the Listing requirements for the NASDAQ?

<< Previous

Bullboard Posts

Next >>

Post by bligickaon Jan 10, 2021 9:32am

177 Views

Post# 32262917

What are the Listing requirements for the NASDAQ?

Below is the guide for the listing requirements for the relevant NASDAQ market - the NASDAQ Capital Market.

The primary consideration is the "Market Value of Publicly Held Stock" which essentially means stock that is in the hands of investors, not insiders. As an example, if your company had pure investors prior to the offering that held shares valued at $5 mill at the valuation of the Reg A+ offering, then NASDAQ will require that you raise at a minimum $10 mill in the Reg A+. $5 mill + $10 mill = $15 mill. The information below is provided courtesy of VentureLawCorp.com

Nasdaq Capital Market – NASDAQ Listing Requirements

Requirements	Equity Standard	Market Value of Listed Securities Standard(3)	Net Income Standard
Net Income from Continuing Operations(In the latest fiscal year or in 2 of last 3 fiscal years)	N/A	N/A	$750,000
Net Tangible Assets	N/A	N/A	N/A
Market Value Publicly Held Stock(1)	$15,000,000	$15,000,000	$5,000,000
Market Value of Listed Securities(2)	N/A	$50,000,000	N/A
# of Shares Publicly Held	1,000,000	1,000,000	1,000,000
# Public Board Lot Holders	300	300	300
Bid price or Closing price(4)	$4.00 $3.00	$4.00 $3.00	$4.00 $3.00
Shareholders Equity	$5,000,000	$4,000,000	$4,000,000
Market Makers	3	3	3
Operating History	2 years	N/A	N/A